BISPECIFIC ANTIBODIES AGAINST CD3*CD19 Russian patent published in 2018 - IPC A61K39/395 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: group of inventions refers to biotechnology, in particular to immunology, and can be used to prepare a recombinant monoclonal bispecific antibody against CD3*CD19. Recombinant monoclonal bispecific antibody against CD3*CD19, including two disulfide-bonded chains, each of which consists of the following domains: VL (CD3)-L1-VH(CD19)-L2-VL(CD19)-L3-VH(CD3)-H-CH2-CH3(IgG2), where VL (CD3) and VH(CD3) – variable domains of the light and heavy chains of the antibody against CD3, VL(CD19) and VH (CD 19) – variable domains of the light and heavy chains of the antibody against CD 19, CH2-CH3 (IgG2) - Fc the IgG2 sequence, characterized by the sequence of SEQ ID NO: 5, L1, L2, L3 – linking sequences consisting of 5-15 amino acids, H is a hinge region characterized by the sequence of SEQ ID NO: 9. Group of inventions also relates to a pharmaceutical composition comprising the above antibody and pharmaceutically acceptable carriers and/or diluents for the treatment of B cell diseases or B cell depletion.

EFFECT: claimed group of inventions makes it possible to obtain a recombinant monoclonal bispecific antibody against CD3*CD19 for the treatment of hematologic malignant diseases of B-cell nature.

13 cl, 5 tbl, 7 dwg